ELVN

Current Thesis

Clinical-stage precision oncology running a 6-week dual-binary corridor: ELVN-001 (allosteric BCR-ABL inhibitor, CML) going toe-to-toe with Novartis's Scemblix (ASC4FIRST 67.7% MMR@48w read at ASCO 2024-06-02, ~$600M annualized run-rate) and ELVN-002 (HER2-selective TKI, >1000x HER2:EGFR per company R&D deck) playing for the post-Nerlynx / pre-tucatinib tox gap. Narrative is ACCELERATING into AACR 2026-04-27 (T-5d from 2026-04-22), with the dominant binary being ASCO 2026-05-31 (T-39d); abstract titles drop ~2026-05-22 and historically move catalyst-biotechs 5–15% on title tease alone. Theme bucket: biotech-precision-therapeutics, tracking ~1.5x XBI beta. This is archetype-5 event-window sizing — NOT a momentum chart trade — and we are inside the pre-binary trim window for any existing longs. New entries here are probes, not fat-pitch builds.

Bull Case

• ELVN-001 ASH 2024 readout (2024-12-09, San Diego): ~44% MMR by week 24 in heavily pre-treated CML incl. T315I — clear delta vs. asciminib ~25% in comparable ASCEMBL population (Novartis, NEJM 2021). Next update slot: ASCO 2026-05-31 window.
• ELVN-002 preclinical profile: >1000x HER2:EGFR selectivity per company R&D deck vs. neratinib ~1x; if Phase-1 human tox at AACR 2026-04-27 confirms the deck in-vivo, the HER2+ metastatic BC optionality re-rates — currently zero credit in consensus models.
• Cash position: ~$280M per Q4 2025 10-Q (filed ~2026-02-27), management-guided runway into 2027 at ~$25M/qtr burn = ~11 quarters. Removes forced-secondary tape risk through both 2026 catalysts, which is non-trivial for a sub-$2B clinical name.
• Tight float ~52M shares — standard clinical-stage squeeze mechanic on positive binary prints. Comps: RLAY +32% post-ASCO 2023 RLY-2608 update; KYMR +41% on ASH 2024 STAT6 Ph1 readout. Spike-and-hold pattern, not fade.
• Risk-on backdrop: XBI above its 200DMA as of April 2026, FDA tone constructive on precision-oncology approvals YTD. Sector regime supports catalyst biotech, not fading it.
• Zero sell-side saturation: 0 headlines in current news feed, no recent filings — narrative is still being built by specialist biotech funds, not CNBC. This is the pre-mainstream window we pay for.

Bear Case

• Scemblix bar is rising, not static: ASC4FIRST (ASCO 2024-06-02) posted 67.7% MMR at week 48 in 1L CML. ELVN-001 must clear a moving target. Any Novartis ASC4START or next-gen asciminib data at ASCO 2026-05-31 that closes the GI-tox / arterial-event gap is a direct kill-shot — this is the single biggest binary-inside-the-binary.
• HER2 TKI graveyard: tucatinib/Tukysa (Seagen→Pfizer) is entrenched in HER2+ BC brain-met, margetuximab approved, T-DXd dominant in 2L+. ELVN-002 needs a differentiated clinical signal, not just preclinical selectivity. PBYI (Puma / neratinib) is cautionary tape for "better TKI" stories that never converted commercially.
• Commercial ceiling visibility: CML incidence ~8,500 US cases/yr. Even a tox-winner ELVN-001 caps sub-blockbuster unless 1L share + ex-US expansion accelerate — which pushes the revenue case out to 2028+.
• Pre-catalyst positioning trap: buyers into AACR T-0 frequently get run over on "in-line" data. DVB catalyst study set: small-cap biotech averages -8 to -12% on "non-surprise" posters. AACR 2026-04-27 is the riskier of the two reads (preclinical/early Ph1 data rarely moves big up; it can move big down on tox).
• Burn math fragility: ~$25M/qtr on $0 revenue. Any Ph2/3 design expansion inflates trial costs; a 2026-H2 offering at weak tape = -15 to -25% overnight.
• Correlation tax at ASCO 2026-05-31: entire precision-oncology cohort (KYMR, RLAY, CRNX, RVMD) shares the weekend. Single-conference correlation ~0.8 means risk is not diversified — it's concentrated.

Setup & Price Structure

• No live price context this cycle — trader must tag 20-EMA, 50DMA, 200DMA before sizing. Do not enter blind. Historical range since 2024-06 SPIO secondary: ~$18–$32.
• Structural gates to confirm before any entry: (a) current price vs 50DMA into AACR week — reclaim = trend intact, rejection = no-touch; (b) weekly close above 20-EMA is the trend-intact gate; violation = stand down; (c) last-3-session volume — catalyst-anticipation biotechs show 1.5–2x avg vol when specialist books are building pre-event.
• Hard floor: $16 — weekly close below $16 on >2x vol wipes the 2024 post-SPO base and the thesis dies with it. This is the invalidation, not a "buy the dip" level.
• Pre-binary trim window per playbook: T-3d AACR (2026-04-24) and T-3d ASCO (2026-05-28). If we are long into those dates, trim ≥50% regardless of price — binary risk reduction is non-negotiable.
• Sizing guidance: MEDIUM conviction → 2–3% position MAX. If probing pre-AACR (T-5d), LOW-sizing 1% — the upside asymmetry is compressed this close to the binary.
• No archetype-6 squeeze characteristics; RSI>75 trim rule does not apply. This is archetype-5 (event risk), trim triggers are date-based, not RSI-based.

Catalyst Calendar (next 30 days)

• 2026-04-27 — AACR Annual Meeting 2026, Chicago (T-5d): ELVN-002 HER2-selective TKI Phase-1 tox/PK poster expected. Secondary ELVN-001 translational data possible. This is the first binary. Abstracts released ~2026-03-25.
• ~2026-05-05 to ~2026-05-10, est. — Q1 2026 earnings window: cash update, burn guide, pipeline recap. Watch for Q1 burn >$30M/qtr (runway invalidation) and any Ph2/3 expansion commentary for ELVN-001. Exact date not yet confirmed; check IR page ~2026-04-28.
• ~2026-05-22, est. — ASCO 2026 abstract title release (T-9d to ASCO): title-only reveal typically moves catalyst biotechs 5–15%. Pre-position decision point, not a trade decision point.
• 2026-05-28 (T-3d ASCO) — MANDATORY trim window: per playbook, pre-binary risk reduction on any existing long.
• 2026-05-31 — ASCO 2026, Chicago: ELVN-001 updated CML Ph1b data (>6-mo follow-up expected). This is the dominant binary. Competitive reads: any Novartis ASC4START / next-gen asciminib presentation is the direct invalidator to watch in the same session.

What Would Change Our Mind

• Upgrade to HIGH / SUPREME: ELVN-001 Ph1b update at ASCO shows >50% MMR@24w with Grade ≥3 AE rate <10% AND no competing ASC4START / next-gen asciminib data that closes the tox gap → 1L CML opportunity re-rates, $280M cash means no overhang, tight float squeezes. Upgrade only POST-data, not pre.
• Upgrade trigger on ELVN-002: AACR 2026-04-27 Phase-1 tox in humans confirms >1000x selectivity translation (no off-target GI/rash cluster) → HER2+ BC optionality goes from zero credit to real credit in the model.
• Downgrade to LOW / SKIP (invalidation):

1. Weekly close below $16 on >2x avg volume — structural base broken, no averaging down, full exit.
2. ELVN-001 Grade ≥3 AE rate >20% at AACR or ASCO — tox is the differentiator; if it breaks, thesis breaks.
3. Novartis posts ASC4START / next-gen asciminib data at ASCO 2026-05-31 with GI-tox or arterial-event profile matching ELVN-001 — direct kill-shot, exit same session.
4. Q1 print shows burn >$30M/qtr — runway-to-2027 story invalidated, secondary risk back on table.
5. Post-AACR trade-through: gap-down >15% on 2026-04-28 that doesn't reclaim within 5 sessions = market has decided, we respect the tape.

• Hard rule: if ANY invalidation triggers, market-sell immediately. "It will come back" is the #1 alpha killer on catalyst biotechs — they don't come back, they re-rate lower and drift.

Correlation Notes

• XBI beta ~1.5x: ELVN amplifies sector moves both directions. XBI below 200DMA = no new entries regardless of narrative.
• Precision-oncology cohort (conference correlation ~0.8): KYMR, RLAY, CRNX, RVMD, REVB all share ASCO 2026-05-31. Do not stack >1 name from this cohort into the same weekend — one portfolio slot for the theme, not four.
• Novartis (NVS) inverse read: positive ASC4START / next-gen asciminib data at ASCO is directly negative for ELVN-001. Monitor NVS conference schedule 48h before ASCO.
• CML comp reads: Ascentage (AAPG/6855.HK) olverembatinib data is a sibling read; positive olverembatinib ex-China data would crowd the T315I / resistant-CML TAM.
• Macro beta: long-duration biotech sensitive to 10Y yields. 10Y >4.75% sustained = XBI tape risk that overrides idiosyncratic catalyst narrative. Check yield regime before sizing.
• Small-cap liquidity: ~52M float, ADV likely <1M shares — slippage on stop-outs is real. Use staggered exits on invalidation, not single market orders >25% of ADV.